<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546429</url>
  </required_header>
  <id_info>
    <org_study_id>04077</org_study_id>
    <nct_id>NCT00546429</nct_id>
  </id_info>
  <brief_title>DePuy Trochanteric (ATN) Nailing Clinical Outcomes Trial</brief_title>
  <acronym>ATN</acronym>
  <official_title>Clinical Trial to Monitor the Clinical Effectiveness of the DePuy ATN Trochanteric Nailing System in the Treatment of Trochanteric Fractures of the Proximal Femur</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DePuy Orthopaedics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DePuy Orthopaedics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor trochanteric fracture healing and review the
      performance of the ATN system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Proximal femoral fractures are among the most common femoral fractures. In the past plates
      and screws were often used to repair these fractures but this treatment had limitations
      including restricted weight bearing. Intermedullary nailing is an alternative to plate and
      screw treatment. Weight bearing is allowed and the procedure can be a less invasive. Among
      intramedullary nailing complications are iatrogenic fractures that can be further divided
      into trochanteric and femoral shaft fractures. Trochanteric fractures often heal without
      additional intervention however femoral shaft fractures usually require an additional
      surgical procedure to facilitate healing. This study will monitor fracture healing using
      clinical and radiographic evaluations of subjects with trochanteric fractures of the proximal
      femur treated with the ATN system.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2006</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Success in Terms of the Merle D'Aubigne Score</measure>
    <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
    <description>Merle D'Aubigne measures pain, mobility and ability to walk using a 0 to 6 scoring scale, with 0 indicating worse outcomes and 6 indicating better outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Lower Extremity Measure (LEM)</measure>
    <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Medical Imaging</measure>
    <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Six Item Screener and Ambulatory Status</measure>
    <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SF-12</measure>
    <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Merle d'Aubigne and Postel</measure>
    <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Femoral Fracture (Proximal)</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Monitoring of trochanteric fractures after treatment with the ATN system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intramedullary nailing</intervention_name>
    <description>Trochanteric nailing for proximal femoral fractures.</description>
    <arm_group_label>A</arm_group_label>
    <other_name>Ace Trochanteric Nail (ATN) system</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Ability to understand and willing to sign the approved consent form.

          -  18 years of age

          -  Skeletally mature

          -  Have stable or unstable proximal femur fracture, including pertrochanteric,
             intertrochanteric, high subtrochanteric or any combination of the AO Proximal Femur
             Fracture Classification

        Exclusion Criteria:

          -  Subjects with concomitant lower extremity injuries or multiple trauma that would
             interfere with normal hip fracture rehabilitation.

          -  Subjects who have isolated or combined medial femoral neck fractures.

          -  Subjects who are unwilling or unable to comply with a rehabilitation program or are
             unwilling or unable to be assessed for 1 year following surgery.

          -  Subjects who are pregnant or breastfeeding.

          -  Subjects who are a prisoner or a known alcohol or drug abuser.

          -  Subjects who have a prior surgical history in the affected hip, or conditions that may
             interfere with outcome or impede healing.

          -  Subjects who have an obliterated medullary canal or other conditions that may
             complicate the reaming process.

          -  Subjects who have evidence of active untreated infections that may spread to other
             areas of the body.

          -  Subjects who have a highly communicable disease or pathology that may limit follow-up.

          -  Subjects, who in the opinion of the Clinical Investigator, have an existing condition
             that indicates the Subject is not a good candidate for the study.

          -  Subjects who are participating in another clinical investigation.

          -  Subjects known to have allergies to titanium, aluminum, vanadium.

          -  Subjects who are currently eligible for workman's compensation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sam Himden</last_name>
    <role>Study Director</role>
    <affiliation>DePuy Orthopaedics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Front Range Orthopaedics</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80910</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orthopaedic Physicians of Colorado</name>
      <address>
        <city>Englewood</city>
        <state>Colorado</state>
        <zip>80110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Erie County Medical Center</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Blue Ridge Bone and Joint</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2007</study_first_submitted>
  <study_first_submitted_qc>October 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2007</study_first_posted>
  <results_first_submitted>September 29, 2010</results_first_submitted>
  <results_first_submitted_qc>November 12, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 10, 2010</results_first_posted>
  <last_update_submitted>February 28, 2012</last_update_submitted>
  <last_update_submitted_qc>February 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Proximal femoral fracture</keyword>
  <keyword>Trochanteric fracture</keyword>
  <keyword>Intramedullary nailing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
    <mesh_term>Femoral Fractures</mesh_term>
    <mesh_term>Hip Fractures</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Between September 2006 &amp; September 2009, 62 subjects were recruited and enrolled at 6 US clinics by orthopaedic surgeons. Each study site could enroll up to 20 subjects (cohorts were re-assigned as necessary to complete enrollment in a timely manner). Recruitment was based on the inclusion and exclusion criteria in the clinical investigation plan.</recruitment_details>
      <pre_assignment_details>This was a non-randomized study so all subjects that met the inclusion/exclusion criteria received the ATN Trochanteric Nail. Consented subjects could be excluded from the trial based on results of pre-operative clinical and/or radiographic evaluations, as per the exclusion criteria in the clinical investigation plan.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DePuy Orthopaedics ATN Trochanteric Nail System</title>
          <description>The participants in this study will undergo treatment of trochanteric fractures using DePuy Orthopaedics ATN Trochanteric Nail System implants and results will be reviewed by clinical and radiographic evaluations.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="62">2 subjects did not have a preoperative Merle D'Aubigne score.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DePuy Orthopaedics ATN Trochanteric Nail System</title>
          <description>The participants in this study will undergo treatment of trochanteric fractures using DePuy Orthopaedics ATN Trochanteric Nail System implants and results will be reviewed by clinical and radiographic evaluations.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="79.2" spread="14.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Success in Terms of the Merle D'Aubigne Score</title>
        <description>Merle D'Aubigne measures pain, mobility and ability to walk using a 0 to 6 scoring scale, with 0 indicating worse outcomes and 6 indicating better outcomes.</description>
        <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>DePuy Orthopaedics ATN Trochanteric Nail System</title>
            <description>The participants in this study will undergo treatment of trochanteric fractures using DePuy Orthopaedics ATN Trochanteric Nail System implants and results will be reviewed by clinical and radiographic evaluations.</description>
          </group>
        </group_list>
        <measure>
          <title>Success in Terms of the Merle D'Aubigne Score</title>
          <description>Merle D'Aubigne measures pain, mobility and ability to walk using a 0 to 6 scoring scale, with 0 indicating worse outcomes and 6 indicating better outcomes.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>4 Week Merle D'Aubigne</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.2" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month Merle D'Aubigne</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.8" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>6 Month Merle D'Aubigne</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Month Merle D'Aubigne</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Lower Extremity Measure (LEM)</title>
        <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Medical Imaging</title>
        <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Six Item Screener and Ambulatory Status</title>
        <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>SF-12</title>
        <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Merle d'Aubigne and Postel</title>
        <time_frame>4 weeks, 3, 6 and 12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>DePuy Orthopaedics ATN Trochanteric Nail System</title>
          <description>The participants in this study will undergo treatment of trochanteric fractures using DePuy Orthopaedics ATN Trochanteric Nail System implants and results will be reviewed by clinical and radiographic evaluations.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>This subject suffered from cancer which is also noted as an adverse event in this study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Implant removal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Bone fracture acetabulum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer</sub_title>
                <description>This subject died and which is also noted as an adverse event in this study.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Respiratory system</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Sam Himden</name_or_title>
      <organization>DePuy Orthopaedics, Inc.</organization>
      <phone>574-372-7231</phone>
      <email>SHimden@its.jnj.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

